PURPOSE: To evaluate multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI/TRUS) fusion targeted biopsy (TB) of the prostate for prostate cancer (PCa) diagnosis. PATIENTS AND METHODS: From April 2013 to January 2014, 53 men were included in this prospective single-centre study. The degree of PCa suspicion from mpMRI findings was classified according to the PI-RADS scoring system. Of these, 50 patients underwent both an mpMRI/TRUS fusion TB and a 10-core systematic biopsy (SB) of the prostate and were eligible for analysis. RESULTS: 225 targeted and 500 systematic cores were included in this study. PCa was histologically confirmed in 52.0% of patients (26/50), whereas TB revealed PCa in 46.0% (23/50) and SB in 36.0% (18/50). TB identified PCa in 16.0% of all patients (8/50) that were missed by SB. All told, the targeted core was 2.8 times more likely to be PCa-positive than the systematic core (29.3 vs. 10.4%). CONCLUSIONS: mpMRI/TRUS fusion TB of the prostate is safe, practicable and may improve PCa diagnosis using fewer biopsy cores compared to SB. 2015 S. Karger AG, Basel
PURPOSE: To evaluate multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI/TRUS) fusion targeted biopsy (TB) of the prostate for prostate cancer (PCa) diagnosis. PATIENTS AND METHODS: From April 2013 to January 2014, 53 men were included in this prospective single-centre study. The degree of PCa suspicion from mpMRI findings was classified according to the PI-RADS scoring system. Of these, 50 patients underwent both an mpMRI/TRUS fusion TB and a 10-core systematic biopsy (SB) of the prostate and were eligible for analysis. RESULTS: 225 targeted and 500 systematic cores were included in this study. PCa was histologically confirmed in 52.0% of patients (26/50), whereas TB revealed PCa in 46.0% (23/50) and SB in 36.0% (18/50). TB identified PCa in 16.0% of all patients (8/50) that were missed by SB. All told, the targeted core was 2.8 times more likely to be PCa-positive than the systematic core (29.3 vs. 10.4%). CONCLUSIONS: mpMRI/TRUS fusion TB of the prostate is safe, practicable and may improve PCa diagnosis using fewer biopsy cores compared to SB. 2015 S. Karger AG, Basel
Authors: Gianluigi Taverna; Giorgio Bozzini; Fabio Grizzi; Mauro Seveso; Alberto Mandressi; Luca Balzarini; Federica Mrakic; Pietro Bono; Oliviero De Franceco; NicolòMaria Buffi; Giovanni Lughezzani; Massimo Lazzeri; Paolo Casale; Giorgio Ferruccio Guazzoni Journal: World J Urol Date: 2015-10-19 Impact factor: 4.226
Authors: Daniel Junker; Thomas R W Herrmann; Markus Bader; Jasmin Bektic; Gregor Henkel; Stephan Kruck; Markus Sandbichler; David Schilling; Georg Schäfer; Udo Nagele Journal: World J Urol Date: 2015-07-01 Impact factor: 4.226
Authors: Jianfeng Xu; W Kyle Resurreccion; Zhuqing Shi; Jun Wei; Chi-Hsiung Wang; S Lilly Zheng; Peter J Hulick; Ashley E Ross; Christian P Pavlovich; Brian T Helfand; William B Isaacs Journal: Prostate Cancer Prostatic Dis Date: 2022-03-28 Impact factor: 5.455